Liposomal Mitigation of IKr Channel Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs that inhibit the IKr channel, such as crizotinib and nilotinib, can cause QT prolongation, leading to cardiac arrhythmias and torsades de pointes, and existing methods fail to effectively mitigate these effects, resulting in drug withdrawals or limited clinical use.
Innovation Solution
Administering these drugs in conjunction with liposomes, which encapsulate or mix with the QT-prolonging agents, significantly decreases their inhibitory effects on the IKr channel, reducing cardiac liability by altering their pharmacokinetic profiles and interaction with cardiac ion channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs that inhibit the IKr channel are administered to treat diseases, then therapeutic efficacy is improved, but QT prolongation and cardiac arrhythmias occur
Solution Approach 1:
Liposomes serve as an intermediary carrier between the IKr channel-inhibiting drug and the cardiac tissue. The liposomal encapsulation modifies drug delivery, reducing direct drug-channel interaction while maintaining therapeutic efficacy. The liposome acts as a protective mediator that controls drug release and minimizes cardiotoxic effects.
Solution Approach 2:
The invention changes the physical and chemical parameters of drug delivery by encapsulating the drug in liposomes. This alters pharmacokinetic parameters such as drug concentration, distribution, and half-life, thereby reducing peak plasma concentrations that cause QT prolongation while maintaining effective tissue levels.
2Reliability
If drugs are administered to achieve therapeutic effects, then disease treatment is improved, but drug withdrawals or limited clinical use result due to cardiac safety issues
Solution Approach 1:
Liposomes enable the drug to achieve therapeutic goals without direct harmful interactions with cardiac channels. The liposomal carrier mediates drug delivery to target tissues while protecting against off-target cardiac effects, thereby expanding clinical applicability.
Solution Approach 2:
The liposomal formulation provides beforehand cushioning against potential cardiac toxicity by pre-encapsulating the drug in a protective carrier that modulates its release profile and reduces peak concentrations that trigger arrhythmias.
3Object-affected harmful factors
If liposomes are used to encapsulate QT-prolonging agents, then cardiac liability is reduced, but drug interaction mechanisms are altered
Solution Approach 1:
Liposomal encapsulation changes pharmacokinetic parameters including absorption, distribution, metabolism, and excretion (ADME). The complex is formed with specific lipid compositions and sizes that control drug release kinetics, creating a modified but predictable pharmacokinetic profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of liposomes with crizotinib and nilotinib decreases their inhibitory effects on the IKr channel, reducing the risk of QT prolongation and associated cardiac issues, potentially preventing drug-induced arrhythmias and prolonging drug efficacy and safety profiles.
Implementation Method 1
liposomes, which encapsulate or mix with the QT-prolonging agents
Implementation Method 2
liposomes, which encapsulate or mix with the QT-prolonging agents
Data Source
AI summary
Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.